A deeper understanding of the molecular mechanism by which FGFR2 contributes to osteoporosis could pave the way for identifying novel therapeutic targets for skeletal disorders characterized by bone fragility or multifactorial osteoporosis. The gene discussed is FGFR2; the disease is osteoporosis.